Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL331035

CCCC[N+](CCCC)(CCCC)CCCC.CS(=O)(=O)[O-]

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol

The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 3/20 0.63
SLC22A2 O15244 1/20 0.55
TSHR P16473 2/20 0.50
ALDH1A1 P00352 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
ALOX15 P16050 1/20 0.50
ALOX12 P18054 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HIF1A Q16665 1/20 0.50
HSD17B10 Q99714 1/20 0.50
DNM1 Q05193 5/20 0.46
RECQL P46063 2/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
EPHX2 P34913 1/20 0.41
BLM P54132 1/20 0.41
LSS P48449 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL31303421 0.97 SLC22A1 (0.60) SLC22A1SLC22A2TSHRALDH1A1TP53
SCHEMBL330915 0.95 SLC22A1 (0.62) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrapentylammonium SCHEMBL306115 0.95 SLC22A1 (0.63) SLC22A1SLC22A2TSHRALDH1A1TP53
SCHEMBL331290 0.92 SLC22A1 (0.65) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrahexylammonium SCHEMBL330698 0.92 SLC22A1 (0.65) SLC22A1SLC22A2TSHRALDH1A1TP53
SCHEMBL330618 0.92 SLC22A1 (0.65) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL243898 0.92 SLC22A1 (0.67) SLC22A1SLC22A2TSHRALDH1A1TP53
SCHEMBL27863447 0.90 SLC22A1 (0.50) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL331003 0.90 SLC22A1 (0.63) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL9795123 0.90 SLC22A1 (0.63) SLC22A1SLC22A2TSHRALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079810-A Aromatic diamine and polyimide containing amido, preparation method and application thereof 2026-05-26 CN claimed
US-20260045538-A1 Catalyst for Lithium-Sulfur Batteries UNIV NORTHEASTERN (US) 2026-02-12 US claimed
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES ENTEGRIS INC (US) 2026-01-15 US claimed
CN-119977847-A Alkyl carboxylic acid-based18Synthesis method of F-labeled alkylsulfonyl fluoride molecule 华中科技大学同济医学院附属同济医院 2025-05-13 CN claimed
CN-119841745-A High-valence iodine (III) carboxylate18Synthesis method of F-labeled alkylsulfonyl fluoride molecule 华中科技大学同济医学院附属同济医院 2025-04-18 CN claimed
CN-119823109-A An electrochromic material electrochromic composition and electrochromic device 吉林大学 2025-04-15 CN claimed
CN-118771310-A No-drying18F-Solution, preparation method and application thereof 四川大学华西医院 2024-10-15 CN claimed
CN-115807348-B Reactive digital printing paste composition for knitted fabric and preparation method thereof 太仓宝霓实业有限公司 2024-07-02 CN claimed
WO-2024081696-A2 COMPOSITIONS CONTAINING PHASE CHANGE MATERIALS, METHODS FOR FORMING OBJECTS USING THE SAME, AND METHOD FOR USING THE SAME PHASE CHANGE ENERGY SOLUTIONS, INC. (US) 2024-04-18 WO claimed
CN-111117594-B Electrochromic material and electrochromic device based on dynamic metal-ligand complexation 吉林大学 2024-03-26 CN claimed
US-20100016517-A1 POLYMERIZATION CATALYST FOR POLYTHIOURETHANE-BASED OPTICAL MATERIAL, POLYMERIZABLE COMPOSITION CONTAINING THE CATALYST, OPTICAL MATERIAL OBTAINED FROM THE COMPOSITION, AND METHOD FOR PREPARING THE OPTICAL MATERIAL MITSUI CHEMICALS, INC (JP) 2010-01-21 US claimed
WO-2010003548-A1 PROCESS FOR PRODUCTION OF RADIOPHARMACEUTICALS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-01-14 WO claimed
EP-2116558-A1 POLYMERIZATION CATALYST FOR POLYTHIOURETHANE OPTICAL MATERIAL, POLYMERIZABLE COMPOSITION CONTAINING THE CATALYST, OPTICAL MATERIAL OBTAINED FROM THE COMPOSITION, AND METHOD FOR PRODUCING THE OPTICAL MATERIAL Mitsui Chemicals, Inc. (JP) 2009-11-11 EP claimed
WO-2003051894-A1 PREPARATION OF IONIC LIQUIDS CYTEC CANADA INC. (CA) 2003-06-26 WO claimed
EP-0585113-B1 Detecting an analyte in the gaseous or vapour phase by bioelectrochemical reactions and media therefor UNIV CRANFIELD (GB) 1999-12-15 EP claimed
EP-0600659-B1 Toner and developer compositions with pyridinium compounds and tetrasubstituted ammonium salts as charge enhancing additives XEROX CORP (US) 1997-07-30 EP claimed
EP-0600659-A1 Toner and developer compositions with pyridinium compounds and tetrasubstituted ammonium salts as charge enhancing additives XEROX CORPORATION (US) 1994-06-08 EP claimed
US-5304449-A Toner and developer compositions with pyridinium compounds and tetrasubstituted ammonium salts as charge enhancing additives XEROX CORPORATION (US) 1994-04-19 US claimed
US-4849531-A Process for the preparation of 2,3-epoxyamides BAYER AKTIENGESELLSCHAFT (DE) 1989-07-18 US claimed
EP-0244717-A2 Process for the preparation of 2,3-epoxyamides BAYER AG (DE) 1987-11-11 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES TET2, ASIC1, PIEZO1 SLC22A1 2747/4885SLC22A2 2992/4885TSHR 2647/4885
US-20260045538-A1 Catalyst for Lithium-Sulfur Batteries KCNA4, CACNA2D4, KCNA1 SLC22A1 799/4885SLC22A2 835/4885TSHR 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.